MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Metrics to compare | MXCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMXCTPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.4x | −2.7x | −0.6x | |
PEG Ratio | −2.36 | −0.36 | 0.00 | |
Price/Book | 2.4x | 3.1x | 2.6x | |
Price / LTM Sales | 11.3x | 4.2x | 3.1x | |
Upside (Analyst Target) | 62.0% | 76.1% | 54.6% | |
Fair Value Upside | Unlock | 0.7% | 7.7% | Unlock |